Literature DB >> 12035934

Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents.

A Patel1, A M Straight, H Mann, E Duffy, C Fenton, C Dinauer, R M Tuttle, G L Francis.   

Abstract

The factor(s) that control metastasis of thyroid carcinoma are unknown, but the matrix metalloproteinases (MMPs) are excellent candidates. MMP-1, membrane-type-1 MMP (MT1-MMP), and tissue inhibitor of MMP-1 (TIMP-1) have all been implicated, but the site of production and importance are disputed. In vitro, normal thyroid cells secrete TIMP-1, while thyroid cancer cells secrete TIMP-1 and MMP-1. However, previous pathological studies identified MMP-1 and TIMP-1 only in the stroma surrounding thyroid carcinoma. These data suggest that thyroid carcinoma or tumor-associated inflammatory cells might secrete a factor(s) which stimulates MMP-1 or TIMP-1 expression by surrounding tissues. We hypothesized that MMP-1, MT1-MMP, and TIMP-1 would be directly expressed by thyroid carcinoma and might promote invasion or metastasis. We used immunohistochemistry to determine the expression of MMP-1, MT1-MMP, and TIMP-1 in 32 papillary thyroid carcinoma (PTC), 10 follicular thyroid carcinoma (FTC) and 13 benign thyroid lesions from children and adolescents. The intensity of staining was graded from absent (grade 0) to intense (grade 3). Average MMP-1 expression (mean relative intensity units+/-SE) was significantly greater among PTC (1.97+/-0.15; p=0.004) and FTC (2.2+/-0.25; p=0.006) compared to benign lesions (1.30+/-0.15); but there was no relationship between MMP-1 expression and invasion, metastasis, or recurrence. Expression of MT1-MMP and TIMP-1 was similar for benign and malignant lesions; but recurrent PTC expressed lower levels of TIMP-1 when compared to non-recurrent PTC (p=0.049). Only the expression of TIMP-1 correlated with the presence of tumor-associated lymphocytes (r=0.35, p=0.032). We conclude that MMP-1, MT1-MMP and TIMP-1 are all expressed by thyroid carcinoma and could be important in promoting recurrence.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12035934     DOI: 10.1007/BF03344028

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

Review 1.  Carcinoma of the thyroid in children--a review.

Authors:  R Feinmesser; E Lubin; K Segal; A Noyek
Journal:  J Pediatr Endocrinol Metab       Date:  1997 Nov-Dec       Impact factor: 1.634

2.  Absence of G(s)alpha gene mutations in childhood thyroid tumors after Chernobyl in contrast to sporadic adult thyroid neoplasia.

Authors:  V Waldmann; H M Rabes
Journal:  Cancer Res       Date:  1997-06-15       Impact factor: 12.701

Review 3.  Matrix metalloproteinases and their inhibitors.

Authors:  A Kugler
Journal:  Anticancer Res       Date:  1999 Mar-Apr       Impact factor: 2.480

4.  Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults.

Authors:  C A Welch Dinauer; R M Tuttle; D K Robie; D R McClellan; R L Svec; C Adair; G L Francis
Journal:  Clin Endocrinol (Oxf)       Date:  1998-11       Impact factor: 3.478

5.  [Study of matrix metalloproteinase-2 and -9 in thyroid papillary cancer].

Authors:  S Maruyama; R Kawata; T Shimada; T Shinomiya; Y Hirata; I Yamamichi; Y Murakami
Journal:  Nihon Jibiinkoka Gakkai Kaiho       Date:  2000-05

6.  The ret/PTC mutations are common in sporadic papillary thyroid carcinoma of children and young adults.

Authors:  C L Fenton; Y Lukes; D Nicholson; C A Dinauer; G L Francis; R M Tuttle
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

7.  A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor accident.

Authors:  S Klugbauer; E Lengfelder; E P Demidchik; H M Rabes
Journal:  Oncogene       Date:  1996-09-05       Impact factor: 9.867

Review 8.  Low prevalence of the ret/PTC3r1 rearrangement in a series of papillary thyroid carcinomas presenting in Belarus ten years post-Chernobyl.

Authors:  A V Pisarchik; G Ermak; E P Demidchik; L S Mikhalevich; N A Kartel; J Figge
Journal:  Thyroid       Date:  1998-11       Impact factor: 6.568

9.  Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.

Authors:  H Nakamura; H Ueno; K Yamashita; T Shimada; E Yamamoto; M Noguchi; N Fujimoto; H Sato; M Seiki; Y Okada
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

10.  Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma.

Authors:  Y Shi; R S Parhar; M Zou; M M Hammami; M Akhtar; Z P Lum; N R Farid; S T Al-Sedairy; M C Paterson
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  7 in total

Review 1.  Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma.

Authors:  Geoffrey B Thompson; Ian D Hay
Journal:  World J Surg       Date:  2004-11-04       Impact factor: 3.352

2.  Discrimination of benign and malignant thyroid nodules by molecular profiling.

Authors:  David J Finley; Baixin Zhu; Catherine B Barden; Thomas J Fahey
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

Review 3.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature.

Authors:  Lun-Xiu Qin; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-17       Impact factor: 4.553

Review 4.  The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication.

Authors:  Laura MacDonald; Jonathan Jenkins; Grace Purvis; Joshua Lee; Aime T Franco
Journal:  Horm Cancer       Date:  2020-06-17       Impact factor: 3.869

5.  MMP-2, MMP-9, TIMP-1, and TIMP-2 in the Peripheral Blood of Patients with Differentiated Thyroid Carcinoma.

Authors:  Wen-Jing Zhang; Bing Song; Tao Yang
Journal:  Cancer Manag Res       Date:  2019-12-23       Impact factor: 3.989

6.  Serum biomarkers of papillary thyroid cancer.

Authors:  Fawaz M Makki; S Mark Taylor; Ali Shahnavaz; Andrew Leslie; Jeffrey Gallant; Susan Douglas; Evelyn Teh; Jonathan Trites; Martin Bullock; Karen Inglis; Devanand M Pinto; Robert D Hart
Journal:  J Otolaryngol Head Neck Surg       Date:  2013-02-07

Review 7.  The Impact of Transcription Factor Prospero Homeobox 1 on the Regulation of Thyroid Cancer Malignancy.

Authors:  Magdalena Rudzińska; Barbara Czarnocka
Journal:  Int J Mol Sci       Date:  2020-05-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.